Chemoimmuntherapie zur neoadjuvanten Behandlung des lokal fortgeschrittenen Non-Small-Cell Lung Cancer (NSCLC)

Histologisches Tumoransprechen ist ein Surrogatparameter für Überleben

Chemoimmunotherapy for neoadjuvant treatment of locally advanced non-small-cell lung cancer (NSCLC)

Histological tumor response is a surrogate parameter for survival

This is a preview of subscription content, access via your institution.

Abb. 1


  1. 1.

    Swaminath A, Vella ET, Ramchandar K et al (2019) Surgery after chemoradiotherapy in patients with stage III (N2 or N3, excluding T4) non-small-cell lung cancer: a systematic review. Curr Oncol 26(3):e398–404

    CAS  Article  Google Scholar 

  2. 2.

    Provencio M, Nadal E, Insa A et al (2020) Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 21(11):1413–1422

    CAS  Article  Google Scholar 

  3. 3.

    Chae YK, Arya A, Iams W et al (2018) Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer 6(1):39.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Forde PM, Chaft JE, Smith KN et al (2018) Neoadjuvant PD‑1 blockade in resectable lung cancer. N Engl J Med 378(21):1976–1986

    CAS  Article  Google Scholar 

  5. 5.

    Walles T (2018) Neoadjuvante Therapie des operablen NSCLC mit Immun-Checkpoint-Inhibitoren. Pneumologe 15:349–350

    Article  Google Scholar 

  6. 6.

    Lücke E, Ganzert C, Föllner S et al (2020) Operabilität und pathologisches Ansprechen des Lungenkarzinoms nach neoadjuvanter Therapie mit Immun-Checkpoint-Inhibitoren. TumorDiagn Ther 41(10):695–701

    Article  Google Scholar 

  7. 7.

    Shu CA, Gainor JF, Awad MM et al (2020) Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 21(6):786–795

    CAS  Article  Google Scholar 

  8. 8.

    Hellmann MD, Chaft JE, William WN et al (2014) Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 15:e42–50

    CAS  Article  Google Scholar 

  9. 9.

    Sorensen JB, Ravn J, Pilegaard HK et al (2013) Surgery for nsclc stages T1–3N2M0 having preoperative pathologically verified N2 involvement: a  prospective randomized multinational phase iii trial by the nordic thoracic oncology group [abstract 7504]. J Clin Oncol.

    Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Zhang XN, Huang L (2017) Neoadjuvant chemotherapy followed by surgery versus upfront surgery in non-metastatic non-small cell lung cancer: systematic review and meta-analysis of randomized controlled trials. Oncotarget 8:90327–90337

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Univ. Prof. Dr. med. Thorsten Walles FETCS.

Ethics declarations


T. Walles gibt an, dass kein Interessenkonflikt besteht.

Additional information


Jens Schreiber, Magdeburg

Peter Zabel, Lübeck/Borstel

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Walles, T. Chemoimmuntherapie zur neoadjuvanten Behandlung des lokal fortgeschrittenen Non-Small-Cell Lung Cancer (NSCLC). Pneumologe 18, 123–125 (2021).

Download citation